Publications by authors named "Ya-Han Lee"
Background: Digital serious games (SGs) have rapidly become a promising strategy for entertainment-based health education; however, developing SGs for children with chronic diseases remains a challenge.
Objective: In this study, we attempted to provide an updated scope of understanding of the development and evaluation of SG educational tools and develop a framework for SG education development to promote self-management activities and behavior change in children with chronic diseases.
Methods: This study consists of a knowledge base and an analytical base.
Article Synopsis
- This study investigated the differences in outcomes between low-dose and standard-dose alteplase in patients with acute ischemic stroke, focusing on bridging therapy for large vessel occlusion.
- The analysis included five studies with 408 patients and measured outcomes like functional independence, successful recanalization, intracerebral hemorrhage, and mortality.
- Results showed that low-dose alteplase did not improve 90-day functional independence compared to standard-dose but had similar rates of successful recanalization, sICH, and mortality, though these results were not statistically significant.
AST-120, an oral spherical activated carbon, may delay the need for kidney dialysis and improve uremia symptoms because it can adsorb acidic and basic organic compounds, especially small-molecule uremic toxins. However, previous studies produced no conclusive evidence regarding the benefits of AST-120 in delaying the progression of chronic kidney disease (CKD). Therefore, this systematic review and network meta-analysis evaluated the effects of AST-120 in patients with CKD.
View Article and Find Full Text PDFArticle Synopsis
- A systematic review and network meta-analysis was conducted to evaluate the effectiveness of small molecule inhibitors and biologics for treating nail psoriasis, as previous research on this topic was unclear.
- The analysis included 39 studies with 15,673 patients, finding that tofacitinib and ixekizumab provided significant improvement in nail psoriasis scores at different time points.
- Ixekizumab showed the highest efficacy for achieving 100% improvement on the Nail Psoriasis Severity Index, but the study faced limitations due to insufficient data and lack of long-term follow-up.
Identifying the optimal fremanezumab treatment strategy is crucial in treating patients with migraines. The optimal strategy was investigated by assessing the cumulative 50% reduction rate (50%CRR), cumulative 75% reduction rate (75%CRR), reduction in the number of migraine days, treatment-related adverse events, and serious adverse events in patients treated with fremanezumab 225 mg monthly (225 mg), 675 mg monthly (675 mg), 900 mg monthly (900 mg), a single high dose of 675 mg (S675mg), 675 mg at baseline with 225 mg monthly (675/225 mg), and placebo. Biomedical databases were searched for randomized controlled trials on this topic, and data were individually extracted.
View Article and Find Full Text PDFBackground: Abuse-deterrent formulations (ADFs) represent one novel strategy for curbing the potential of opioid abuse.
Objective: We aim to compare and contrast the characteristics and applications of current abuse-deterrent opioid products in clinical practice.
Methods: Literature searches were conducted in databases (Pubmed Medline, International Pharmaceutical Abstracts, Google Scholar) and official reports.